Clinical Trials
38 trialsNCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT04458909 2025-10-03
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT03656536 2025-08-24
FIGHT-302
Incyte Corporation
Phase 3 Terminated
NCT03773302 2024-05-08
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT05493501 2024-05-02
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc.
Phase 3 Terminated
NCT00617656 2024-01-30
BREC
Spanish Lung Cancer Group
Phase 3 Terminated
NCT00658593 2023-08-04
Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
Canadian Cancer Trials Group
Phase 3 Terminated
NCT04163900 2023-05-24
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
Phase 3 Terminated
NCT03690739 2022-02-24
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
AGO Research GmbH
Phase 3 Terminated
NCT01956812 2021-08-16
PANCRIT®-1
Gilead Sciences
Phase 3 Terminated
NCT02951156 2020-12-17
Javelin DLBCL
Pfizer
Phase 3 Terminated
NCT00054197 2020-10-05
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
CTI BioPharma
Phase 3 Terminated
NCT02715804 2020-07-14
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Halozyme Therapeutics
Phase 3 Terminated
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated
NCT02082522 2019-08-28
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Concordia Laboratories Inc.
Phase 3 Terminated
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT01314027 2019-07-25
Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer
University of Zurich
Phase 3 Terminated
NCT03348904 2019-06-13
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Incyte Corporation
Phase 3 Terminated
NCT02409355 2019-02-15
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
Hoffmann-La Roche
Phase 3 Terminated
NCT01232556 2019-01-08
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Pfizer
Phase 3 Terminated
NCT01041781 2018-07-23
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT01900327 2018-05-11
NEOPA
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT02359162 2018-05-09
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
Sun Yat-sen University
Phase 3 Terminated
NCT00526643 2017-03-28
CAPPA-2
National Cancer Institute, Naples
Phase 3 Terminated
NCT00863512 2017-03-27
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00920153 2016-09-16
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
French Innovative Leukemia Organisation
Phase 3 Terminated
NCT00574275 2016-06-07
VANILLA
Sanofi
Phase 3 Terminated
NCT00345059 2016-01-14
DISTAL-2
National Cancer Institute, Naples
Phase 3 Terminated
NCT00031837 2015-10-14
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
University of Rochester
Phase 3 Terminated
NCT00254904 2015-03-30
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
Pfizer
Phase 3 Terminated
NCT00440622 2013-02-13
Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Hellenic Oncology Research Group
Phase 3 Terminated
NCT00003803 2012-07-18
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00442026 2012-06-27
Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC
Hellenic Oncology Research Group
Phase 3 Terminated
NCT00237575 2012-05-23
Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer
University of Kentucky
Phase 3 Terminated
NCT00470340 2011-05-05
GEMOXIAL
Assistance Publique - Hôpitaux de Paris
Phase 3 Terminated
NCT00191477 2009-10-28
Instillation of Gemcitabine in Patients With Superficial Bladder Cancer
Eli Lilly and Company
Phase 3 Terminated
NCT00358566 2008-05-19
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
Pharmexa A/S
Phase 3 Terminated